Proteome Sciences PLC Director/PDMR Shareholding (3722X)
August 09 2018 - 8:23AM
UK Regulatory
TIDMPRM
RNS Number : 3722X
Proteome Sciences PLC
09 August 2018
09 August 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences
Fund ("Vulpes") that on 7 August 2018, it purchased 1,400,000
ordinary shares of 1p each in the capital of the Company ("Ordinary
Shares") at 3.50p per Ordinary Share (the "Purchase"). Following
the purchase, Vulpes has a total direct and indirect interest in
57,759,431 equivalent to 19.6% of Proteome Sciences' total issued
share capital.
The Company would also like to announce that by virtue of Martin
Diggle being a Director of both Vulpes Investment Management and
the Company, he now has an interest in 57,759,431 Ordinary Shares
of the Company representing 19.6% of the issued share capital of
the Company.
The below notification is made in accordance with the
requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Martin Diggle
------------------------------------- --------------------------------
Reason for the notification
-----------------------------------------------------------------------
a) Position/status: Non-Executive Director
------------------------------------- --------------------------------
b) Initial notification/Amendment: Initial Notification
------------------------------------- --------------------------------
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
-----------------------------------------------------------------------
a) Name: Proteome Sciences Plc
------------------------------------- --------------------------------
b) LEI: 213800Q62ICXANKU2986
------------------------------------- --------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary Shares of 1p nominal
instrument, type of instrument: value
Identification code:
GB0003104196
------------------------------------- --------------------------------
b) Nature of the transaction: Purchase of Ordinary Shares
------------------------------------- --------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
3.50 1,400,000
---------
------------------------------------- --------------------------------
d) Aggregated information: Single transaction as in
* Aggregated volume: 4 c) above
Average Volume(s)
Price
* Price: 3.50 1,400,000
---------
------------------------------------- --------------------------------
e) Date of the transaction: 7 August 2018
------------------------------------- --------------------------------
f) Place of the transaction: London Stock Exchange,
AIM (XLON)
------------------------------------- --------------------------------
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043
2116
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
finnCap Limited (Nominated Adviser & Broker)
Geoff Nash/Hannah Boros (Corporate Finance) Tel: +44 (0)20 7220
Abigail Wayne (Broking) 0500
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers
for diagnostic and treatment applications in important areas of
human therapeutics such as cancer, stroke and Alzheimer's disease,
and these are available for license.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSSFFEUFASEEA
(END) Dow Jones Newswires
August 09, 2018 08:23 ET (12:23 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024